Sunshine Biopharma (SBFM) Director Natan David Receives Award

What Happened
Natan David, a director of Sunshine Biopharma, was granted a stock award of 58,300 shares on August 7, 2026. The Form 4 records this as an acquisition (transaction code A) at $0.00 per share (total cash reported $0). This was an equity award/grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-08-07
• Transaction type/code: Grant / A (stock award)
• Shares acquired: 58,300 at $0.00 per share (reported cash = $0)
• Shares owned after transaction: Not disclosed in this filing
• Footnote: F1 — represents a stock award to the reporting person
• Filing date: 2026-08-11 (filed within the SEC’s reporting window — on time)

Context

• This was an award/compensation grant, not a sale or market purchase. Stock awards are commonly used for compensation and may be subject to vesting or other restrictions; the filing does not detail vesting terms or restrictions.
• Awards do not necessarily indicate immediate buying or selling intent; they reflect compensation arrangements rather than open-market sentiment.